Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a ...
Ewing sarcoma arm advances to second lead-in safety dosing cohort in Sarcoma trial evaluating seclidemstat in combination with chemotherapy agents in patients with relapsed/refractory Ewing sarcoma ...
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback